Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
4 United States sites
18 to 50 Years
Phase 1/Phase 2
This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
1 United States site
8 to 21 Years
Hemoglobin SS
Phase 4
This study will evaluate two genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) products - OTQ923 and HIX763 - each reducing the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.
3 United States sites
2 to 40 Years
HbSS, HbSC
Phase 1/Phase 2
This is a study to evaluate the effect of voxelotor on daily physical activity and sleep quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD) and chronic moderate anemia.
10 United States sites
12 to 55 Years
SCA
Phase 4
The overall purpose of this proposed study is to improve management of vaso-occlusive episodes (VOEs) in adult EDs.
8 United States sites
18 to 45 Years
Hb SS, Hb SC
N/A
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of FT-4202 and test how well FT-4202 works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
23 United States sites
12 to 65 Years
Phase 2/Phase 3
The ASCENT Trial is a single arm, multi-center, phase II study.
7 United States sites
< 20 Years
Phase 2
Approximately 60 subjects will be enrolled into this double-blind, placebo-controlled study for the Deferoxamine Intradermal Delivery Patch (DIDP).
4 United States sites
> 18 Years
Phase 1/Phase 2
This project proposes to develop, test and evaluate targeted interventions to improve clinical provider prescribing of and patient adherence to hydroxyurea (HU).
8 United States sites
15 to 45 Years
Hb SS, Hb SC
N/A
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.
9 United States sites
9 Brazil sites
6 United Kingdom sites
5 Italy sites
5 Germany sites
5 Belgium sites
4 Spain sites
3 Netherlands sites
3 Colombia sites
3 Greece sites
3 France sites
3 India sites
2 Panama sites
2 Canada sites
2 Lebanon sites
2 Turkey sites
1 South Africa site
1 Kenya site
1 United Arab Emirates site
1 Finland site
1 Ghana site
1 Jordan site
1 Oman site
> 12 Years
Phase 3
